A peer-reviewed study published in Cell shows the good and the bad (mostly) about the COVID-19 shots. The study’s findings help explain why adverse reactions happen with the COVID-19 (CV19) injections.
The authors compared antibodies by people who recovered from CV19 and those vaccinated with the Pfizer, Moderna, AstraZeneca, Sputnik, and Sinopharm vaccines.
Findings
The study has three significant discoveries. (1) Immune imprinting of COVID-19 infection and COVID shots. (2) Spike proteins can be found for two days in the blood after the CV19 jabs, and (3) the detection of spike antigens in the lymph nodes 60 days post-COVID shots.
What is immune imprinting?
Immune imprinting is the preferential response of the immune system to make antibodies to the first viral variant that it encountered. Immune imprinting is also known as antigenic imprinting or “original antigenic sin” and explains why some vaccines are not 100 % effective, especially in older people.
Immune imprinting commonly happens in influenza vaccines. The antibodies that form in response to the most recent influenza vaccine received will have more affinity to the first influenza virus encountered many years ago.
In the COVID-19 pandemic, the first SARS-CoV-2 viral strain is the Wuhan-type. RNA viruses like the flu and SARS-CoV-2 frequently mutate, which is why vaccines developed for the flu and coronaviruses are not very effective.
The study showed that people who recovered from CV19 and those given the CV19 injections (all shots are based on the Wuhan strain) have more antibodies against the Wuhan type than the other variants. But there is a difference. The COVID shots tend to make antibodies towards different variants right away, while the CV19 recovered people took longer to make the variant-directed antibodies.
This article contains block quotes from Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
Vaccine antibody levels similar to severe COVID-19
The antibody levels of the Stanford clinic’s vaccinees were identical to those who had severe COVID-19 and higher than those who had mild to moderate CV19.
Stanford BNT162b2 vaccinee RBD and spike IgG concentrations
were comparable to those of severely ill patients and higher than
those of mildly or moderately ill patients for anti-RBD antibodies
at day 42 (page 7)
That may sound good since the more antibodies, the better, right? Not so. Low antibody levels are good enough for CV19 protection. That’s because the cellular immune response can also contribute to protection.[3]
Plus, patients with severe COVID-19 get sick due to the autoimmune disease manifested by high antibody titers. Here are some examples.
Fujii and colleagues reported that people who recovered from CV19 with high antibody levels showed more elevated anti-SSA/Ro antibodies. [2] Anti-SSA antibodies are found in 60 to 90% of patients with Primary Sjögrens syndrome and 30 to 40% of a subset of SLE (Systemic Lupus Erythematosus) patients. Sjögren’s syndrome is an autoimmune disease presenting as dry eyes and mouth.
Shi et al. found that elevated antiphospholipid antibodies are seen in severe COVID-19 patients. Antiphospholipid antibodies activate the inner lining of the blood vessels and form blood clots.[4]. Blood clots and multi-system organ failure are seen in severe CV19.
Cairoli and Espinosa discussed the possible autoimmune diseases triggered or flared up after CV19 injections.[5]
SARS-CoV-2 mRNA detected up to 60 days in the lymph nodes in vaccinees
The mRNA of the spike protein injected with the CV19 shots makes the body produce spike protein. The spike protein then stimulates an immune response. To find out how that happens, the study authors did lymph node biopsies and found that mRNA can be present for up to 60 days after the second shot of Moderna and Pfizer.
Immunohistochemical staining for spike antigen in mRNA- vaccinated patient lymph nodes varied between individuals but showed abundant spike protein in germinal centers 16 days post-second dose, with spike antigen still present as late as 60 days post-second dose.
The research also found SARS-CoV-2 antigens in the lymph nodes of patients who died from CV1. This explains why people who survive severe CV-19 can develop autoimmune diseases. [6]
Spike mRNA last up to eight weeks after the COVID-19 shots
Another discovery is that SARS-CoV-2 mRNA is still present in the lymph nodes for up to eight weeks.
In contrast to disrupted germinal centers in lymph nodes during infection, mRNA vaccination stimulates robust germinal centers containing vaccine mRNA and spike antigen up to 8 weeks postvaccination in some cases.
This contrasts with what the CDC says about the COVID-19 mRNA on their website.
The mRNA and the spike protein don’t last long in the body.
Our cells break down mRNA and get rid of it within a few days after vaccination.
So why is the mRNA still present after eight weeks? It could be due to the pseudouridine (Ψ) in the mRNA shots (Moderna and Pfizer). The Ψ is present to inhibit mRNA degradation so that the mRNA can last long enough to enter the cells. [7]. Apparently, the pseudouridine worked very well in preserving the mRNA.
Detection of spike protein in the blood after the shots
The last finding is critical and helps explain the immediate adverse effects and deaths due to the CV19 injections. (Emphasis added)
At least some portion of spike antigen generated after administration of (Pfizer) BNT162b2 becomes distributed into the blood.
We detected spike antigen in 96% of vaccinees in plasma collected 1–2 days after the prime injection, with antigen levels reaching as high as 174 pg/mL.
At later time points after vaccination, the concentrations of spike antigen in blood quickly decrease although spike is still detectable in plasma in 63% of vaccinees 1 week after the first dose.
The SARS-CoV-2 spike protein causes inflammation and thrombosis wherever it goes in the body. The spike protein can go to the heart, brain, and lungs.
The latest release of the VAERS data on February 11, 2022, shows the following deaths after receiving the CV19 shots:
- 953 cases died within 24 hours
- 1,384 died within 48 hours
- 2,488 people started to have adverse effects within 48 hours
An analysis of the COVID-19 vaccine death reports shows that among those > 65 years old, 50% die within 48 hours, and 80% die in one week. [8]
This study was supported by the National Institute of Health, the National Institute of Allergy and Infectious Diseases, and the Bill and Melinda Gates Foundation.
My thoughts
In summary, this study demonstrated immune imprinting among the CV19 vaccines and explained why they are not as effective as claimed. The detection of spike antigens in the blood destroyed the CDC claim that the vaccines are “safe” because the spike proteins don’t circulate in the blood after the shots.
Finally, the mRNA of the spike proteins in the lymph nodes at 60 days can also explain the chronic inflammation, autoimmune diseases, and post-vaccination syndrome that happen after the injections. (if they prolonged the study, it might be longer).
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
Click on some ads, so the website gets revenue. If you find value in the articles, please consider donating to show your support.
References:
- Röltgen et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022; S0092-8674(22)00076-9. doi:10.1016/j.cell.2022.01.018
- Fujii H, et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: High levels of anti-SSA/Ro antibodies in COVID-19. Clin Rheumatol. 2020 Nov;39(11):3171-3175. doi: 10.1007/s10067-020-05359-y. Epub 2020 Aug 25. PMID: 32844364; PMCID: PMC7447083.
- McMahan, K., Yu, J., Mercado, N.B. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021). https://doi.org/10.1038/s41586-020-03041-6.
- Shi, H., et al. (2022) Endothelial cell-activating antibodies in COVID-19. Arthritis & Rheumatology. doi.org/10.1002/art.42094.
- Cairoli E, Espinosa G. Autoimmune diseases and vaccines against COVID-19. Decision-making in uncertain scenarios. Med Clin (Engl Ed). 2021;157(5):247-252. doi:10.1016/j.medcle.2021.05.003
- Arunachalam, P.S., Scott, M.K.D., Hagan, T. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021). https://doi.org/10.1038/s41586-021-03791-x
- Boo, S.H., Kim, Y.K. The emerging role of RNA modifications in the regulation of mRNA stability. Exp Mol Med 52, 400–408 (2020). https://doi.org/10.1038/s12276-020-0407-z
- Mclachlan, Scott & Osman, Magda & Dube, Kudakwashe & Chiketero, Patience & Choi, Yvonne & Fenton, Norman. (2021). Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim: Results and Analysis. 10.13140/RG.2.2.26987.26402.
© 2018 – 2022 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment